Repotrectinib Shows Significant Clinical Activity in ROS1+ NSCLC

2018-11-01

TRIDENT-1 study is an ongoing phase I/II trial aims to study the safety and efficacy of next generation tyrosine kinase inhibitor (TKI) repotrectinib in patients with solid tumors harboring ALK, ROS1, or NTRK1-3 rearrangements. Recently, the interim analysis results were presented at the 19th World Conference on Lung Cancer (WCLC). In non-small cell lung cancer (NSCLC) patients carrying ROS1 fusion (n=27), the objective response rate (ORR) was 80% (95% CI, 44-97) for TKI-naive patients and 18% (95% CI, 4-44) for TKI-refractory patients. In addition, tumor regression occurred in four patients harboring the crizotinib-resistant ROS1 G2032R mutation after receiving repotrectinib. These results suggested that repotrectinib may provide a new opportunity in ROS1 fusion-positive NSCLC and overcome resistance in refractory patients.


Source:

Lin J, Kim D, Drilon A, et al. Safety and Preliminary Clinical Activity of Repotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC.

Presented at: the IASLC 19th World Conference on Lung Cancer; September 23-26; Toronto, Canada. Abstract OA02.02.